Prognostic Significance of Immune Cell Populations Identified by Machine Learning in Colorectal Cancer Using Routine Hematoxylin and Eosin-Stained Sections.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 08 2020
Historique:
received: 07 01 2020
revised: 16 04 2020
accepted: 14 05 2020
pubmed: 23 5 2020
medline: 28 10 2021
entrez: 23 5 2020
Statut: ppublish

Résumé

Although high T-cell density is a well-established favorable prognostic factor in colorectal cancer, the prognostic significance of tumor-associated plasma cells, neutrophils, and eosinophils is less well-defined. We computationally processed digital images of hematoxylin and eosin (H&E)-stained sections to identify lymphocytes, plasma cells, neutrophils, and eosinophils in tumor intraepithelial and stromal areas of 934 colorectal cancers in two prospective cohort studies. Multivariable Cox proportional hazards regression was used to compute mortality HR according to cell density quartiles. The spatial patterns of immune cell infiltration were studied using the G Immune cell densities measured by the automated classifier demonstrated high correlation with densities both from manual counts and those obtained from an independently trained automated classifier (Spearman's ρ 0.71-0.96). High densities of stromal lymphocytes and eosinophils were associated with better cancer-specific survival [ These findings highlight the potential for machine learning assessment of H&E-stained sections to provide robust, quantitative tumor-immune biomarkers for precision medicine.

Identifiants

pubmed: 32439699
pii: 1078-0432.CCR-20-0071
doi: 10.1158/1078-0432.CCR-20-0071
pmc: PMC7442724
mid: NIHMS1596991
doi:

Substances chimiques

Biomarkers, Tumor 0
Eosine Yellowish-(YS) TDQ283MPCW
Hematoxylin YKM8PY2Z55

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4326-4338

Subventions

Organisme : NCI NIH HHS
ID : R35 CA197735
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA118553
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA137178
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK098311
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA169141
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA197879
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA127003
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA190673
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA222940
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA230873
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA055075
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA151993
Pays : United States
Organisme : Cancer Research UK
ID : UK C10674/A27140
Pays : United Kingdom

Informations de copyright

©2020 American Association for Cancer Research.

Références

Clin Cancer Res. 2018 Dec 15;24(24):6125-6135
pubmed: 30049748
Gut. 2012 Jun;61(6):794-7
pubmed: 22490520
PLoS One. 2017 Dec 6;12(12):e0188799
pubmed: 29211768
J Clin Oncol. 2008 Dec 1;26(34):5630-7
pubmed: 18936473
Lung Cancer. 2018 Mar;117:73-79
pubmed: 29409671
Int J Cancer. 2016 Sep 1;139(5):1129-39
pubmed: 27074317
Eur J Epidemiol. 2018 Apr;33(4):381-392
pubmed: 29264788
Cancer Immunol Res. 2019 Mar;7(3):388-400
pubmed: 30665890
Br J Cancer. 2019 Apr;120(9):871-882
pubmed: 30936499
J Immunol. 2007 Dec 15;179(12):8454-62
pubmed: 18056392
Stat Methods Med Res. 2013 Jun;22(3):278-95
pubmed: 21220355
Int J Cancer. 2016 Jul 15;139(2):446-56
pubmed: 26939802
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901
pubmed: 30006429
Annu Rev Pathol. 2019 Jan 24;14:83-103
pubmed: 30125150
Cancer Treat Rev. 2020 Feb;83:101949
pubmed: 31869737
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Gut. 2009 Jan;58(1):90-6
pubmed: 18832519
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369
pubmed: 29632055
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Histopathology. 2018 Aug;73(2):327-338
pubmed: 29575153
PLoS One. 2013 May 29;8(5):e64814
pubmed: 23734221
J Clin Oncol. 2017 Jun 1;35(16):1836-1844
pubmed: 28406723
N Engl J Med. 2007 May 24;356(21):2131-42
pubmed: 17522398
Cancer Discov. 2018 Jun;8(6):730-749
pubmed: 29510987
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Nat Rev Immunol. 2015 Mar;15(3):160-71
pubmed: 25698678
J Mol Diagn. 2007 Jul;9(3):305-14
pubmed: 17591929
Biomed Res Int. 2018 Jan 28;2018:9095275
pubmed: 29619379
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Pathol. 1999 Dec;189(4):487-95
pubmed: 10629548
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Lab Invest. 2018 Jan;98(1):15-26
pubmed: 29251737
J Mol Diagn. 2005 Aug;7(3):413-21
pubmed: 16049314
Comput Struct Biotechnol J. 2018 Feb 09;16:34-42
pubmed: 30275936
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
N Engl J Med. 2012 Oct 25;367(17):1596-606
pubmed: 23094721
Clin Cancer Res. 2017 Jul 15;23(14):3847-3858
pubmed: 28108544
J Mol Diagn. 2010 Mar;12(2):177-83
pubmed: 20093385
Cell Rep. 2016 Apr 26;15(4):857-865
pubmed: 27149842
Hum Pathol. 2017 Oct;68:193-202
pubmed: 28882699
Breast Cancer Res. 2015 Sep 22;17(1):131
pubmed: 26395345
Cell Rep. 2018 Apr 3;23(1):181-193.e7
pubmed: 29617659
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
Mod Pathol. 2016 May;29(5):516-27
pubmed: 26916075
PLoS One. 2010 Aug 25;5(8):e12420
pubmed: 20811638
Nat Hum Behav. 2018 Jan;2(1):6-10
pubmed: 30980045

Auteurs

Juha P Väyrynen (JP)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.

Mai Chan Lau (MC)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Koichiro Haruki (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Sara A Väyrynen (SA)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Andressa Dias Costa (A)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Jennifer Borowsky (J)

Conjoint Gastroenterology Department, QIMR Berghofer Medical Research Institute, Queensland, Australia.

Melissa Zhao (M)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Kenji Fujiyoshi (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Kota Arima (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Tyler S Twombly (TS)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Junko Kishikawa (J)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Simeng Gu (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Saina Aminmozaffari (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Shanshan Shi (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Yoshifumi Baba (Y)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Naohiko Akimoto (N)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Tomotaka Ugai (T)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Annacarolina Da Silva (A)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Mingyang Song (M)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.

Kana Wu (K)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Andrew T Chan (AT)

Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Reiko Nishihara (R)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Charles S Fuchs (CS)

Yale Cancer Center, New Haven, Connecticut.
Department of Medicine, Yale School of Medicine, New Haven, Connecticut.
Smilow Cancer Hospital, New Haven, Connecticut.

Jeffrey A Meyerhardt (JA)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Marios Giannakis (M)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Shuji Ogino (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, Massachusetts.

Jonathan A Nowak (JA)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. janowak@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH